Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High throughput surface plasmon resonance imaging method for clinical detection of presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.

MethodsX·2021
Same author

Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.

Biosensors & bioelectronics·2021
Same author

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.

Journal of extracellular vesicles·2019
Same author

Parallel probing of drug uptake of single cancer cells on a microfluidic device.

Electrophoresis·2017
Same author

Metastasis and Circulating Tumor Cells.

EJIFCC·2016
Same author

Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS.

Genome medicine·2013

Related Experiment Video

Updated: May 15, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Interpretation of changes in circulating tumor cell counts.

Frank Aw Coumans1, Sjoerd T Ligthart, Leon Wmm Terstappen

  • 1Department of Medical Cell BioPhysics, University of Twente, Enschede, Netherlands.

Translational Oncology
|January 17, 2013
PubMed
Summary
This summary is machine-generated.

Monitoring circulating tumor cells (CTCs) can guide cancer therapy. A static cutoff for CTCs best indicates treatment effectiveness, with complete elimination being the goal within 10-12 weeks.

More Related Videos

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Related Experiment Videos

Last Updated: May 15, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Area of Science:

  • Oncology
  • Cancer Biomarkers
  • Clinical Trial Analysis

Background:

  • Circulating tumor cells (CTCs) are prognostic indicators in cancer.
  • Evaluating therapy response based on CTC reduction is crucial for treatment guidance.

Purpose of the Study:

  • To determine the optimal method for evaluating CTC count reduction post-therapy.
  • To establish a reliable metric for assessing treatment efficacy using CTCs.

Main Methods:

  • Enumeration of CTCs using the CellSearch system in 111 metastatic breast and 185 metastatic prostate cancer patients.
  • Analysis of various methods for expressing CTC count changes in relation to overall survival (OS).

Main Results:

  • A static CTC cutoff demonstrated the strongest correlation with OS (Cox hazard ratio of 2.1).
  • Relative difference methods for CTC changes were less effective predictors of survival.
  • A lookup table was developed to interpret the significance of CTC changes.

Conclusions:

  • A static CTC threshold is the most effective method for assessing therapy response.
  • The ultimate therapeutic goal should be the complete eradication of CTCs.
  • A treatment duration of 10-12 weeks is suggested to observe significant effects on CTC levels.